VVOS

Rating neutralAI MemoPost-earnings T+3

Vivos Therapeutics

As of 2026-08-20/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-20 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 results provide a mixed operating checkpoint • 2026-11-18

Base target: $0 / p=55% prob

Biggest risk

The company remains financially fragile, with persistent operating losses, limited liquidity, execution dependence on SCN and provider expansion, and meaningful financing or dilution risk.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

Q2 operating momentum, stronger gross margin, and service revenue associated with the SCN model could support a highly asymmetric micro-cap recovery if growth scales and cash burn improves.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-20

Base target

p=55%

Bull target

p=20%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings liquidity and loss profile remain the near-term overhang
SCN and provider-alliance scaling could create operating leverage
Q2 operating momentum, stronger gross margin, and service revenue associated with the SCN model could support a highly asymmetric micro-cap recovery if growth scales and cash burn improves.

BearKey bullets

Analyst coverage and revision data are too thin to validate the post-earnings thesis.
Liquidity and continuing cash burn may require additional financing.
Micro-cap volatility, dilution, and potential listing or capital-structure pressure can dominate operating results.

WatchKey bullets

Q2 results provide a mixed operating checkpoint

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $0 (p=55%)

Target spread vs base: +100% / -67%

Scenario probabilities

Bull Target: $1 (p=20%)Base Target: $0 (p=55%)Bear Target: $0 (p=25%)

Commentary

News flow is sparse and primarily earnings-summary driven. The post-earnings price action remains weak, with the latest available quote around $0.276 and down roughly 5.6% from the prior close. Analyst revisions and options/social data are unavailable, so missing reaction data is not positive evidence. The result is a cautious monitoring setup rather than a high-conviction turnaround thesis.

As of 2026-08-20 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Q2 operating momentum, stronger gross margin, and service revenue associated with the SCN model could support a highly asymmetric micro-cap recovery if growth scales and cash burn improves.

Bear Case

The company remains financially fragile, with persistent operating losses, limited liquidity, execution dependence on SCN and provider expansion, and meaningful financing or dilution risk.

Drivers

Scannable catalysts and supporting factors

Post-earnings liquidity and loss profile remain the near-term overhang
SCN and provider-alliance scaling could create operating leverage

Scenarios

Bull Target (Scenario probability)

$1 / p=20% prob

Base Target (Scenario probability)

$0 / p=55% prob

Bear Target (Scenario probability)

$0 / p=25% prob

Analysis 2026-08-20 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.15

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-18
Q2 results provide a mixed operating checkpoint
Q2 revenue growth and stronger gross margin support the SCN-led operating thesis, but higher operating expenses and continued operating losses limit the quality of the beat. The earnings call and quarterly filing are the primary confirmation points [#EARNINGS-TRANSCRIPT-2026Q2] [#SEC-10Q-2026-08-14].
Prob 100.00% • Move 12.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Post-earnings liquidity and loss profile remain the near-term overhang
2026-11-18
The mid-August Q2 update showed improving revenue and gross margin, but the company remained loss-making and liquidity remains constrained. Management's earnings-call risk disclosures explicitly include cash-flow and profitability uncertainty [#EARNINGS-TRANSCRIPT-2026Q2], while the latest 10-Q confirms the reporting period and remains the key filing for balance-sheet monitoring [#SEC-10Q-2026-08-14].
Prob 70% • Move -15% • Priced-in 65%

Long-term Catalysts

Months to a year

SCN and provider-alliance scaling could create operating leverage
2026-12-31
A durable rerating depends on Vivos converting service-led growth and its sleep-center/provider model into repeatable revenue, lower cash burn, and eventual positive cash flow. The call discusses plans for the remainder of 2026, but the evidence remains early-stage and execution-dependent [#EARNINGS-TRANSCRIPT-2026Q2] [#10-K-2026-04-15].
Prob 30% • Move 70% • Priced-in 25%

Risks

Analyst coverage and revision data are too thin to validate the post-earnings thesis.
Liquidity and continuing cash burn may require additional financing.
Micro-cap volatility, dilution, and potential listing or capital-structure pressure can dominate operating results.
Persistent operating losses and rising operating expenses could delay the path to profitability.
Revenue growth may remain concentrated in the SCN/service model and may not translate into durable product demand or operating leverage.

Peers

Symbol	Summary
AMIX	Same-sector micro-cap candidate; useful mainly as a financing and commercialization-risk reference, not a direct sleep-apnea treatment peer.
LUCY	Similar-sized healthcare equipment candidate from the packet, but product overlap is loose and comparative operating conclusions are limited.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-20

Loading AI feed…

Symbol

Summary

AMIX

Same-sector micro-cap candidate; useful mainly as a financing and commercialization-risk reference, not a direct sleep-apnea treatment peer.

LUCY

Similar-sized healthcare equipment candidate from the packet, but product overlap is loose and comparative operating conclusions are limited.